

## CURRICULUM VITAE

Mithat Gönen, Ph.D.

**NAME:** Mithat Gönen, Ph.D.

**DATE OF BIRTH:** February 2, 1968

**PLACE OF BIRTH:** Ankara, Turkey

**NATIONALITY:** Turkish

**OFFICE ADDRESS:**

Memorial Sloan-Kettering Cancer Center  
1275 York Avenue Box 44  
New York, NY 10021

Telephone: (646) 735-8111  
Fax: (646) 735-0010  
e-mail: gonenm@mskcc.org

**EDUCATION:**

1986-1991	B.S. Electrical Electronics Engineering	Middle East Technical University
1992-1993	M.S. Industrial Engineering	Stanford University
1993-1996	M.S. Statistics	Texas Tech University
1993-1996	Ph.D. Statistics	Texas Tech University

**POSITIONS AND APPOINTMENTS:**

2005-present Associate Attending Biostatistician, Memorial Hospital for Cancer and Allied Diseases, New York, NY and Associate Member, Memorial Sloan-Kettering Cancer Center, New York, NY

1999-2005 Assistant Attending Biostatistician, Memorial Hospital for Cancer and Allied Diseases, New York, NY and Assistant Member, Memorial Sloan-Kettering Cancer Center, New York, NY

1998-1999 Senior Statistical Scientist, Applied Logic Associates, Houston, TX

1996-1998 Biostatistician, Applied Logic Associates, Houston, TX

**SCIENTIFIC SOCIETIES:**

- American Statistical Association
- International Biometric Society

**GRANTS**

October 2006

Page 1 of 13

- PI: "Targeted Blood Management for Surgical Resections" funded by MSK Society, 2005-2007. \$118,845.
- PI: "Individualized Risk Prediction of Complications to Liver Surgery" funded by MSK Society, 2006-2007. \$51,032.

**HONORS AND AWARDS:**

1996            International Biometric Society (ENAR), Student Paper Award

1992-1996    Turkish Council for Higher Education, Scholarship for Graduate Study

1986-1990    Sabanci Foundation, Scholarship for Higher Education

**OTHER ACTIVITIES:****Invited and Elected Positions:**

- Member, Committee on International Relations in Statistics, American Statistical Association, 2006-2008.
- Member, Common Data Elements Committee For Phase II Clinical Trials, National Cancer Institute, Cancer Therapy Evaluation Program.
- Member, Data Safety and Monitoring Board, "Antiviral and Antifibrotic Liver Therapy of HCV<sup>+</sup> Drinkers." NIH-supported multi-center randomized trial. 2004-2008
- Member, Data Safety and Monitoring Board, "Home-Based Blood Pressure Interventions for African Americans." NIH-supported multi-center randomized trial. 2005-2009
- Member, NIH Review Panel "Genetic and Molecular Mechanisms of CAD Susceptibility and Progression"
- Member, NIH Review Panel "Specialized Centers For Cell-Based Therapy (SCCT) For Heart, Lung, and Blood Diseases and Data and Coordinating Center (DCC)"
- Member, NCI Subcommittee J on Population and Patient-Based Training, 2006-2008.
- Vice President, New York City Chapter of the American Statistical Association, 2003-2006
- Executive Committee Member, New York City Chapter of the American Statistical Association, 2001-2003
- Treasurer, Houston Area Chapter of the American Statistical Association, 1997-1999

**Teaching:**

1999-2001    Lecturer of Biostatistics, Cornell University

1994-1995    Teaching Assistant, Texas Tech University

1991-1992    Teaching Assistant, Texas Tech University

1990-1991    Teaching and Research Assistant, Middle East Technical University

**Invited Seminars Presented:**

October 2006

1. *Bayesian analysis of variance components with Dirichlet priors.* Conference of Texas Statisticians, Houston, Texas, April 1997.
2. *Bayesian analysis of intraclass correlations in the mixed linear model.* Universite Catholique de Louvaine, Institute of Statistiques, Louvain-la-neuve, Belgium, March 1998.
3. *Bayesian methods in signal processing.* Rice University, Digital Signal Processing Research Group, Houston, Texas, October 1998.
4. *Bayes and frequentist methods for multiple inferences in drug experiments.* 1999 International Biometric Society (ENAR) Regional Conference, Atlanta, GA, March 1999.
5. *Bayesian multiple testing with correlated priors.* Southern Research Council on Statistics (SRCOS) Summer Conference, Mountain View, AR, June 1999.
6. *Bayesian multiple testing of multiple endpoints in clinical trials.* M.D. Anderson Cancer Center, Department of Biostatistics, Houston, TX, March 2000.
7. *A Bayesian look at the two-sample multivariate problem: connections with multiple testing.* New York State Psychiatric Institute, New York, NY, November 2002.
8. *Analysis of clustered binary pairs.* Texas Tech University, Department of Mathematics and Statistics, Lubbock, TX, April 2003.
9. *Testing marginal homogeneity with clustered binary data.* Penn State Medical School, Hershey, PA, September 2003.
10. *Clinical trials and molecular biology.* New Jersey Cancer Institute, New Brunswick, NJ. March 2005.
11. *Receiver operating characteristic curves.* SAS Users Group International 31, San Fransisco, CA. March 2006.
12. *Receiver operating characteristic curves.* Northeast SAS Users Group, Philaladelphia, PA September 2006.
13. *Estimation Of Concordance Probability With Censored Data And Its Applications In Cancer Staging.* Columbia Univeristy Department of Biostatistics, October 2006.

CURRICULUM VITAE

Mithat Gönen, Ph.D.

**LANGUAGES:**

Spoken: English, Turkish  
Written: English, Turkish

**MARITAL STATUS:**

Married

**SPOUSE'S NAME:** Elza Erkip

**DEPENDENT #:**

Two

**MILITARY SERVICE:**

Performed obligatory service in Turkish army, 1996.

**PEER-REVIEWED PUBLICATIONS:**

1. Westfall P, **Gönen M**: Asymptotic properties of ANOVA Bayes Factors. *Communications in Statistics: Theory and Methods* 1996;25:3103-3123.
2. **Gönen M**, Puri M, Ruymgaart F, Van Zuijlen M: The limiting density of unit-root test statistics: unknown mean, dependent errors. *Journal of Time Series Analysis*. 2000;21:249-260.
3. **Gönen M**: A Bayesian analysis of intraclass correlations in the mixed linear model. *Communications in Statistics: Theory and Methods* 2000;29:1451-1464.
4. Sharma S, **Gönen M**: Fluoropyrimidine chemotherapy improves 1-year mortality in people with stage IV or unresectable colorectal cancer compared with supportive care. *J of Evidence-Based Oncology* 2000;1:116.
5. Ramos CD, Erdi YE, **Gönen M**, Riedel ER, Yeung WD, Macapinlac HA, Chisin R, Larson SM: FDG-PET standardized uptake values in normal anatomical structures using IRSAC and FBP. *J Nucl Med* 2001;28:155-164.
6. Abraham M, **Gönen M**, Kraus D: Complications of Type I thyroplasty and arytenoid adduction. *Laryngoscope* 2001;111:1322-1329.
7. Yeung HWD, Cody HS, Turlakow A, Riedel ER, Fey J, **Gönen M**, Nunez R, Yeh SD, Larson SM: LSG and SNL at surgery in breast cancer patients: Comparison between one-day and two-day protocols. *J Nucl Med* 2001;42:420-423.
8. Kemeny N, **Gönen M**, Sullivan D, Schwartz L, Benedetto F, Saltz L, Stockman J, Fong Y, Jarnagin W, Bertino J: A Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. *J Clin Oncol* 2001;19:2687-2695.
9. Jarnagin WR, Fong Y, DeMatteo RP, **Gönen M**, Burke EC, Bodniewicz J, Youseff M, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Ann Surg* 2001;234:507-517.
10. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, **Gönen M**, Schwartz G: Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. *Clin Cancer Res* 2001;7:4209-4219.
11. **Gönen M**, Panageas KS, Larson SM: Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. *Radiology* 2001;221:763-767.
12. Turlakow A, Larson S, Coakley F, Akhurst T, **Gönen M**, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P: Local detection of prostate-cancer by positron-emission-tomography with 2-fluorodeoxy-glucose-comparison of filtered back-projection and

- iterative reconstruction with segmented attenuation correction. *Quarterly J Nucl Med* 2001;45:235-244.
13. Nuñez R, Macapinlac HA, Yeung HWD, Akhurst T, Sai SD, Osman I, **Gönen M**, Riedel E, Scher HI, Larson SM: Combined F-18-FDG and C-11 methionine PET scans in patients with newly progressive metastatic prostate cancer. *J Nucl Med* 2002;43:46-55.
  14. Akhurst T, Downey RJ, Ginsberg MS, **Gönen M**, Bains M, Korst R, Ginsberg RJ, Rusch V, Larson SM: An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. *Ann of Thorac Surg* 2002;73:259-264.
  15. Petrowski H, **Gönen M**, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y: 2<sup>nd</sup> liver resections are safe and effective treatment for recurrent colorectal cancer hepatic metastases from colorectal cancer – A bi-institutional analysis. *Ann Surg* 2002;235:863-870.
  16. Ross PL, Gerigk C, **Gönen M**, Yossepowitch O, Cagiannos I, Sogani PC, Scardino PT, Kattan MW: Comparisons of nomograms and urologists' predictions in prostate cancer. *Sem Urolo Oncol* 2002;20:82-88.
  17. Panageas KS, Smith A, **Gönen M**, Chapman PB: An optimal 2-stage phase II design utilizing complete and partial response information separately. *Control Clin Trials* 2002; 23:367-379.
  18. Kemeny N, Tong W, **Gönen M**, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA: Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. *Ann Oncol.* 2002;13:1490-1496.
  19. Etchebehere EC, Macapinlac HA, **Gönen M**, Humm K, Yeung HW, Akhurst T, Scher HI, Larson SM: Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of 18F-FDG PET. *Q J Nucl Med.* 2002.46:122-130.
  20. Holen KD, Klimstra DK, Hummer A, **Gönen M**, Conlon K, Brennan M, Saltz LB. Clinical Characteristics and Outcomes From an Institutional Series of Acinar Cell Carcinoma of the Pancreas and Related Tumors. *J Clin Oncol.* 2002;20:4673-4678.
  21. Wong RJ, Lin DT, Schoder H, Patel SG, **Gönen M**, Wolden S, Pfister DG, Shah JP, Larson SM, Kraus DH. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. *J Clin Oncol.* 2002;20:4199-4208.
  22. Jarnagin WR, **Gönen M**, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH. Improvement in perioperative outcome after hepatic resection – analysis of 1803 consecutive cases over the past decade. *Ann Surg.* 2002;236:397-407.

23. Stanziale SF, Petrowsky H, Joe JK, Roberts GD, Zager JS, Gusani NJ, Ben-Porat L, **Gönen M**, Fong Y. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. *Surgery* 2002;132:353-359.
24. Allen PJ, Stojadinovic A, Ben-Porat L, **Gönen M**, Kooby D, Blumgart L, Paty P, Fong Y. The management of variant arterial anatomy during hepatic arterial infusion pump placement. *Ann Surg Oncol*. 2002;9:875-80.
25. Pandit-Taskar N, **Gönen M**, Krug L, Larson SM. Prognostic value of 18FDG-PET imaging in small cell lung cancer. *European J Nucl Med & Molecular Imaging* 2003;30:78-84.
26. **Gönen M**, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. *J Clin Oncol* 2003;21:406-412.
27. Downey RJ, Akhurst T, Ilson D, Ginsberg, R, Bains MS, **Gönen M**, Koong H, Gollub M, Larson SM, Minsky B, Zakowski M, Turnbull A, Rusch V. Whole body 18FDG-PET measurement of the response of esophageal cancer to induction therapy: results of a prospective trial. *J Clin Oncol* 2003;21:428-432.
28. D'Angelica M, Fong Y, Weber S, **Gönen M**, DeMatteo RP, Conlon K, Blumgart LH, Jarnagin WR. A prospective analysis of staging laparoscopy in 401 patients with primary and secondary hepatobiliary malignancy. *Ann Surg Oncol*. 2003;10:183-189.
29. **Gönen M**, Westfall PH, Johnson WO. Bayesian multiple testing for two-sample multivariate endpoints. *Biometrics*. 2003;59:76-82.
30. Shoup M, **Gönen M**, D'Angelica M, Jarnagin W, DeMatteo R, Schwartz LH, Tuorto S, Blumgart LH, Fong Y. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. *J Gastrointest Surg* 2003;7:325-330.
31. Kooby DA, Stockman J, Ben-Porat L, **Gönen M**, Jarnagin WR, DeMatteo RP, Tuorto S, Wuest D, Blumgart LH, Fong Y. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. *Ann Surg*. 2003;237:860-870
32. **Gönen M**. Planning for subgroup analysis: A case study in metastatic colorectal cancer. *Control Clin Trials*. 2003;24:355-363.
33. Flores RM, Akhurst T, **Gönen M**, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. *J Thorac Cardiovasc Surg*. 2003;126:11-16.
34. Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, **Gönen M**, Wilson K, Minsky BD. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and

- concurrent radiotherapy in locally advanced esophageal cancer. *J Clin Oncol.* 2003;1;21:2926-32
35. Kemeny N, Jarnagin W, **Gönen M**, Stockman J, Blumgart L, Sperber D, Hummer A, Fong Y. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. *J Clin Oncol.* 2003;21:3303-3309
  36. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, **Gönen M**, Kattan MW, Catalona WJ. A Nomogram For Predicting a Positive Repeat Prostate Biopsy in Patients With a Previous Negative Biopsy Session. *J Urol* 2003;170:1184-1188.
  37. Yeung HWD, Grewal RK, **Gönen M**, Schoder H, Larson SM. Patterns of 18F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET. *J Nucl Med* 2003;44:1789-1796
  38. Hann LE, Kim CM, **Gönen M**, Barakat R, Choi PH, Bach AM. Sonohysterography Compared With Endometrial Biopsy for Evaluation of the Endometrium in Tamoxifen-Treated Women. *J Ultrasound Med* 2003;22:1173-1179.
  39. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, **Gönen M**, Reuter V, Scardino PT. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. *J Urol.* 2003;170:2292-2295.
  40. Weitz J, D'Angelica M, **Gönen M**, Klimstra D, Coit DG, Brennan MF, Karpeh MS. Interaction of Splenectomy and Perioperative Blood Transfusions on Prognosis of Patients With Proximal Gastric and Gastroesophageal Junction Cancer. *J Clin Oncol.* 2003;21:4597-4603
  41. Jung C, Motwani M, Kortmanky J, Sirotnak FM, She Y, **Gönen M**, Haimowitz-Friedman A, Schwartz GK. The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates {gamma}-Irradiation Induced Apoptosis in Colon and Gastric Cancer Cells. *Clin. Cancer Res.*2003;9:6052-6061.
  42. Kooby DA, Fong Y, Suriawinata A, **Gönen M**, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR. Impact of steatosis on perioperative outcome following hepatic resection. *J Gastrointest Surg.* 2003;7:1034-1044.
  43. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, **Gönen M**, Kelsen DP. Phase I Trial of Combined-Modality Therapy for Localized Esophageal Cancer: Escalating Doses of Continuous-Infusion Paclitaxel With Cisplatin and Concurrent Radiation Therapy. *J Clin Oncol* 2004;22:45-52.
  44. Schoder H, Yeung HWD, **Gönen M**, Kraus D, Larson SM. Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. *Radiology* 2004;231:65-72

45. Schoder H, Erdi YE, Chao K, **Gönen M**, Larson SM, Yeung HWD. Clinical Implications of Different Image Reconstruction Parameters for Interpretation of Whole-Body PET Studies in Cancer Patients. *J Nucl Med.* 2004;45:559-566.
46. Weitz J, D'angelica M, Jarnagin W, **Gönen M**, Fong Y, Blumgart L, DeMatteo R. Selective use of diagnostic laparoscopy prior to planned hepatectomy for patients with hepatocellular carcinoma. *Surgery.* 2004;135:273-281.
47. Stanziale SF, Petrowsky H, Adusumilli PS, Ben-Porat L, **Gönen M**, Fong Y. Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. *Clin Cancer Res.* 2004 1;10:3225-3232.
48. Brenner B, Shah MA, **Gönen M**, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. *BR.J Cancer* 2004;4;90:1720-1726.
49. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, **Gönen M**, Segal NH, Maki RG, Succi ND, DeMatteo RP, Besmer P. Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. *Clin Cancer Res* 2004;2010:3282-3290.
50. Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, **Gönen M**, Kattan MW, Onyebuchi CN, Scardino PT. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. *Cancer* 2004;100:2655-2663.
51. **Gönen M**. Sample size and power for McNemar's test with clustered data. *Statist. Med.* 2004;23:2283-2294.
52. Carlo WF, Hummer AJ, Schwartz L, Sullivan D, **Gönen M**, Jarnagin W, Fong Y, Kemeny N. Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. *J Surg Oncol.* 2004;87:85-90.
53. Downey RJ, Akhurst T, **Gönen M**, Vincent A, Bains MS, Larson SM, Rusch V. Preoperative F-18 Fluorodeoxyglucose-Positron Emission Tomography Maximal Standardized Uptake Value Predicts Survival After Lung Cancer Resection. *J Clin Oncol* 2004; 22; 3255–3260.
54. Pandit-Taskar N, Schoder H, **Gönen M**, Larson SM, Yeung HWD. Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET. *AJR AM J Roentgenol* 2004;183:1143-1147.
55. D'Angelica M, **Gönen M**, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma. *Ann Surg.* 2004;240:808-816.

56. Yanke BV, **Gönen M**, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. *J Urol.* 2005;173:421-424.
57. Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, **Gönen M**, O'Reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors. *J Clin Oncol.* 2005;23:1875-1884.
58. Kemeny N, **Gönen M**. Hepatic arterial infusion after liver resection.(Letter) *N Engl J Med.* 2005;352:734-735.
59. Spanknebel K, Coit DG, Bieligk SC, **Gönen M**, Rosai J, Klimstra DS. Characterization of Micrometastatic Disease in Melanoma Sentinel Lymph Nodes by Enhanced Pathology: Recommendations for Standardizing Pathologic Analysis. *Am J Surg Pathol.* 2005;29:305-317.
60. Hawkins WG, Dematteo RP, Cohen MS, Jarnagin WR, Fong Y, D'Angelica M, **Gönen M**, Blumgart LH. Caudate hepatectomy for cancer: A single institution experience with 150 patients. *J Am Coll Surg.* 2005;200:345-52.
61. **Gönen M**. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials. *Contemp Clin Trials* 2005;26:131-140.
62. Shah MA, Kemeny N, Hummer A, Drobnjak M, Motwani M, Cordon-Cardo C, **Gönen M**, Schwartz GK. *Drg1* Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes. *Clin Cancer Res* 2005 11:3296-3302.
63. Schoder H, Noy A, **Gönen M**, Weng L, Green D, Erdi YE, Larson SM, Yeung HW. Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. *J Clin Oncol.* 2005;23:4577-4580.
64. Vural B, Chen LC, Saip P, Chen YT, Ustuner Z, **Gönen M**, Simpson AJ, Old LJ, Ozbek U, Gure AO. Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters. *Cancer.* 2005;103:2575-2583.
65. Yeung HW, Schoder H, Smith A, **Gönen M**, Larson SM. Clinical Value of Combined PET/CT Imaging in the Interpretation of FDG PET Studies in Cancer Patients. *Mol Imaging Biol.* 2005;7:229-235
66. Shah MA, Kortmansky J, Motwani M, Drobnjak M, **Gönen M**, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol. *Clin Cancer Res* 2005;11:3836-3845.
67. Specht, Kattan MW, **Gönen M**, Fey J, VanZee KJ. Predicting Nonsentinel Node Status After Positive Sentinel Lymph Biopsy for Breast Cancer: Clinicians Versus Nomogram. *Ann Surg Oncol.* 2005;12:654-659.
68. Schoder H, Hermann K, **Gönen M**, Hricak H, Eberhard S, Scardino P, Scher H, Larson SM. 2-[18F] fluoro-2-deoxyglucose positron emission tomography for the detection of

- disease in patients with prostate-specific antigen relapse after radical prostatectomy. *Clin Cancer Res.* 2005;11:4761-4769.
69. **Gönen M.** Planning a dose-response study when doses are subject-specific. *Statist Med.* 2005; 24:2613-2623.
70. Maluccio M, Covey AM, Gandhi R, **Gönen M**, Getrajdman GI, Brody LA, Fong Y, Jarnagin W, D'Angelica M, Blumgart L, Dematteo R, Brown KT. Comparison of Survival Rates after Bland Arterial Embolization and Ablation Versus Surgical Resection for Treating Solitary Hepatocellular Carcinoma up to 7 cm. *J Vasc Interv Radiol.* 2005;16:955-961.
71. Kemeny N, Jarnagin W, Paty P, **Gönen M**, Schwartz L, Morse M, Leonard G, D'Angelica M, Dematteo R, Blumgart L, Fong Y. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. *J Clin Oncol.* 2005;23:4888-4896.
72. Kemeny N, Eid A, Stockman J, **Gönen M**, Schwartz L, Tetzlaff E, Paty P. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. *J Surg Oncol.* 2005;18:91:97-101.
73. **Gönen M**, Johnson WO, Lu T, Westfall PH. The Bayesian two-sample t-test. *The American Statistician*, 2005; 59: 252-257.
74. Kraus DH, **Gönen M**, Mener D, Brown AE, Bilsky MH, Shah JP. A Standardized Regimen of Antibiotics Prevents Infectious Complications in Skull Base Surgery. *Laryngoscope.* 2005;115:1347-1357.
75. Jarnagin WR, Zager JS, Hezel M, Stanziale SF, Adusumilli PS, **Gönen M**, Ebright MI, Culliford A, Gusani NJ, Fong Y. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. *Cancer Gene Ther.* 2006; 13:326-334.
76. Bennett J, **Gönen M**, D'Angelica M, Jaques DP, Brennan MF, Coit DG. Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? *J Am Coll Surg.* 2005;201:503-510.
77. Fong Y, **Gönen M**, Rubin M, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. *Ann Surg.* 2005;242:540-547.
78. Liau KH, Ruo L, Shia J, Padera A, **Gönen M**, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP. Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. *Cancer*, 2006;104:1945-1955.
79. Howard MA, Cordeiro P, Disa J, Samson W, **Gönen M**, Schoelle H, Mehrara B. Free tissue transfer in the elderly: incidence of perioperative complications following microsurgical reconstruction of 197 septuagenarians and octogenarians. *Plast Reconstr Surg.* 2005;116:1659-68.
80. **Gönen M**, Heller G. Concordance probability and discriminatory power in proportional hazards regression. *Biometrika*, 2005;92:965-970.

81. Gure AO, Chua R, Williamson B, **Gönen M**, Ferrera CA, Gnjatic S, Ritter G, Simpson AJG, Chen YT, Old LJ, Altorki NK. Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer. *Clin Cancer Res* 2005;11: 8055-8062.
82. Robbins RJ, Wan Q, Grewal RK, Reibke R, **Gönen M**, Strauss HW, Tuttle RM, Drucker W, Larson SM. Real-time Prognosis for Metastatic Thyroid Carcinoma Based on FDG-PET Scanning. *J Clin Endocrinol Metab.* 2006; 91:498-505.
83. Mullerad M, Eisenberg DP, Akhurst TJ, Adusumilli PS, Riedl CC, Bhargava A, **Gönen M**, Finn R, Scardino PT, Fong Y. Use of Positron Emission Tomography to Target Prostate Cancer Gene Therapy by Oncolytic Herpes Simplex Virus. *Mol Imaging Biol.* 2006; 8:30-35.
84. Toner LE, Vrhovac R, Smith EA, Jeffrey G, Heaney M, **Gönen M**, Teruya-Feldstein J, Sirotnak F, O'Connor OA. The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma. *Clin Cancer Res* 2006;12 924-932
85. D'Angelica M, Maddineni S, Fong Y, Martin RC, Cohen MS, Ben-Porat L, **Gönen M**, DeMatteo RP, Blumgart LH, Jarnagin WR. Optimal Abdominal Incision for Partial Hepatectomy: Increased Late Complications with Mercedes-type Incisions Compared to Extended Right Subcostal Incisions. *World J Surg.* 2006; 30:410-418.
86. Yoon S, Kim SH, **Gönen M**, Heffernan N, Detwiler KY, Jarnagin WR, D'Angelica M, Blumgart LH, Tanabe KK, DeMatteo RP. Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. *Ann Surg Oncol.* 2006;13:353-362.
87. Brady MS, Akhurst T, Spanknebel K, Hilton S, **Gönen M**, Patel A, Larson S. Utility of Preoperative [(18)F]Fluorodeoxyglucose-Positron Emission Tomography Scanning in High-Risk Melanoma Patients. *Ann Surg Oncol.* 2006;13:525-532.
88. Rizk N, Downey RJ, Akhurst T, **Gönen M**, Bains M, Larson SM, Rusch V. Preoperative FDG-PET SUV predicts survival after esophageal adenocarcinoma resection. *Ann Thorac Surg.* 2006;81:1076-1081.
89. Jarnagin WR, Klimstra DS, Hezel M, **Gönen M**, Fong Y, Roggin K, Cyrenes K, DeMatteo RP, D'Angelica M, Blumgart LH, Singh B. Differential cell cycle regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables and clinical outcome. *J Clin Oncol.* 2005;23:1875-1884.
90. Port E, Yeung H, **Gönen M**, Liberman L, Caravelli J, Borgen P, Larson S. (18)F-2-Fluoro-2-Deoxy-D: -Glucose Positron Emission Tomography Scanning Affects Surgical Management in Selected Patients With High-Risk, Operable Breast Carcinoma. *Ann Surg Oncol.* 2006;13:677-684.
91. Santiago JF, **Gönen M**, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of (18)F-FDG PET scans on clinical management of 133 breast cancer patients. *Q J Nucl Med Mol Imaging.* 2006;50:61-67.

92. Schoder H, Carlson DL, Kraus DH, Stambuk HE, **Gönen M**, Erdi YE, Yeung HWD, Huvos AG, Shah JP, Larson SM, Wong RJ. 18F-FDG PET/CT for Detecting Nodal Metastases in Patients with Oral Cancer Staged N0 by Clinical Examination and CT/MRI. *J Nucl Med* 2006;47:755-762
93. Stiles BM, Adusumilli PS, Stanziale SF, Eisenberg DP, Bhargava A, Kim TH, Chan MK, Huq R, **Gönen M**, Fong Y. Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer. *Int J Oncol.* 2006;28:1429-1439.
94. Fong Y, Wagman L, **Gönen M**, Crawford J, Reed W, Swanson R, Pan C, Ritchey J, Stewart A, Choti M. Evidence-based gallbladder cancer staging: changing cancer staging by analysis of data from the National Cancer Database. *Annals of Surgery*; 2006;243:767-771.
95. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. *Ann Oncol.* 2006 Jun 20; *Ann Oncol*, 2006;17:1404-1411
96. Budak-Alpdogan T, Przybylowski M, **Gönen M**, Sadelain M, Bertino J, Riviere I. Functional Assessment of the Engraftment Potential of Gammaretrovirus-Modified CD34(+) Cells, Using a Short Serum-Free Transduction Protocol. *Hum Gene Ther.* 2006; 17:780-94.
97. Grobmyer SR, Wang L, **Gönen M**, Fong Y, Klimstra D, D'angelica M, Dematteo RP, Schwartz L, Blumgart LH, Jarnagin WR. Perihepatic Lymph Node Assessment in Patients Undergoing Partial Hepatectomy for Malignancy. *Ann Surg.* 2006;244:260-264.
98. Gerecitano J, Goy A, Wright J, Macgregor-Cortelli B, Neylon E, **Gönen M**, Esseltine D, Boral A, Schenkein D, Busam K, Teruya-Feldstein J, Sachs D, O'connor OA. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? *Br J Haematol.* 2006;134:391-398.
99. Pryma DA, Schoder H, **Gönen M**, Robbins RJ, Larson SM, Yeung HW. Diagnostic Accuracy and Prognostic Value of 18F-FDG PET in Hurthle Cell Thyroid Cancer Patients. *J Nucl Med.* 2006;47:1260-1266.
100. Allen PJ, D'Angelica M, **Gönen M**, Jaques DP, Coit DG, Jarnagin WR, DeMatteo R, Fong Y, Blumgart L, Brennan MF. A Selective Approach to the Resection of Cystic Lesions of the Pancreas: Results From 539 Consecutive Patients. *Ann Surg.* 2006 Oct;244(4):572-582.
101. Flores R, Akhurst T, **Gönen M**, Zakowski M, Dycoco J, Larson SM, Rusch VW. Positron emission tomography predicts survival in malignant pleural mesothelioma. *J Thorac Cardiovasc Surg.* 2006 Oct;132(4):763-8.